Home・Lista de Ações・Cogent Biosciences Inc

Cogent Biosciences Inc

Fechado

42.25 1.64

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

42.1

Máximo

42.54

Indicadores-chave
By Trading Economics
Rendimento	5.1M -97M
EPS	-0.53
Funcionários	258
EBITDA	14M -95M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+26.8% upside

Dividendos
By Acuity
Próximos Ganhos	11 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	366M 6.6B
Abertura anterior	40.61
Fecho anterior	42.25

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de ago. de 2026, 23:51 UTC

U.S. Labor Market Contraction Fuels Stock Market Rally and Eases Fed Rate Hike Expectations

8 de ago. de 2026, 23:51 UTC

U.S. equity markets surge to record highs as July job data signals potential pause in Federal Reserve interest rate hikes, while European stocks also reach all-time highs amid mixed economic signals.

8 de ago. de 2026, 23:51 UTC

U.S. equity markets surge to record highs as disappointing July employment data shifts investor sentiment towards a potential pause in Federal Reserve interest rate hikes.

8 de ago. de 2026, 23:51 UTC

U.S. equity markets surge as disappointing July jobs data lowers Fed rate hike expectations, with S&P500 hitting record high.

8 de ago. de 2026, 23:51 UTC

US Producer Price Inflation Expected to Rise 0.1% in July Amid Labor Market Concerns and Fed Rate Speculations

8 de ago. de 2026, 23:51 UTC

Correlated Moves

Macro News

Bitcoin trades higher as a surprising jobs report fuels speculation of interest rate cuts, potentially benefiting cryptocurrencies. Ethereum also sees a slight price increase.

8 de ago. de 2026, 23:41 UTC

Core PPI Release on August 13, 2026, Expected to Show Moderate Inflation Increase Amid Mixed Labor Market Signals and Cautious Investor Sentiment.

8 de ago. de 2026, 23:31 UTC

BoJ's Upcoming Summary of Opinions on August 9, 2026, May Signal Cautious Monetary Policy Amidst Mixed Market Sentiment and Global Rate Hike Discussions.

8 de ago. de 2026, 23:21 UTC

Core Inflation Rate Expected at 2.5% Amid Mixed Economic Data and Job Losses, Influencing Fed's Interest Rate Decisions

8 de ago. de 2026, 23:21 UTC

Core Inflation Rate Release on August 12, 2026 Expected to Show +0.2% Increase Amid Mixed Economic Signals and Job Market Concerns

8 de ago. de 2026, 23:21 UTC

Investors Brace for July CPI Release Amid Mixed Employment Reports and Inflation Concerns Impacting Fed Policy Decisions

8 de ago. de 2026, 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.1% in July Amid Mixed Economic Signals and Labor Market Concerns

8 de ago. de 2026, 23:21 UTC

US CPI YoY Inflation Rate Expected at 3.4% Amid Mixed Economic Signals and Job Losses, Influencing Fed's Interest Rate Decisions

8 de ago. de 2026, 23:21 UTC

Investors Brace for Volatility Ahead of August CPI Release Amid Mixed Economic Signals and Fed Rate Speculation

8 de ago. de 2026, 23:11 UTC

Brazil's Retail Sales Report on August 13 Expected to Reveal Consumer Spending Trends Amid Economic Uncertainties.

8 de ago. de 2026, 22:41 UTC

U.S. 30-Year Mortgage Rates Hit Year-High of 6.81% Amid Weak Job Growth and Fed Rate Speculation

8 de ago. de 2026, 22:41 UTC

Cardano is trading lower today, continuing a downward trend since Friday. The asset remains above its 20-day moving average and near its one-month range high.

8 de ago. de 2026, 22:31 UTC

Brazil's Inflation Rate MoM Release on August 11, 2026, Sparks Caution Among Analysts Amid Global Economic Uncertainties.

8 de ago. de 2026, 22:31 UTC

Brazil's Inflation Rate Release on August 11, 2026 Expected to Reflect Moderate Trends Amid Global Economic Concerns.

8 de ago. de 2026, 22:11 UTC

UK Housing Market Faces Caution Ahead of RICS House Price Balance Release Amid Stagnant Prices and Economic Uncertainty

8 de ago. de 2026, 21:51 UTC

Japan's Current Account Surplus Forecasted at JPY 1,512 Billion Amid Forex Interventions and Cautious Market Sentiment Ahead of August Release.

8 de ago. de 2026, 21:41 UTC

South Korea's unemployment rate expected to hold steady at 2.7% amid global economic uncertainties, with market sentiment cautiously optimistic ahead of August release.

8 de ago. de 2026, 21:31 UTC

UK Retail Sales Monitor YoY for July 2026 Expected to Rise 1.5% Amid Mixed Sentiment and Economic Pressures

8 de ago. de 2026, 21:21 UTC

India's July 2026 Inflation Rate Release Expected to Show Stability at 4.54% Amid Geopolitical Tensions and Food Price Pressures

8 de ago. de 2026, 21:21 UTC

Brazil's Central Bank to announce interest rate decisions amid global economic uncertainties on August 10, 2026.

8 de ago. de 2026, 20:31 UTC

Euro Area's Q2 Employment Change Data Release on August 14 Sparks Cautious Optimism Amid Rising Unemployment and Mixed Economic Signals.

8 de ago. de 2026, 20:31 UTC

Euro Area Expected to Report €2.2 Billion Trade Deficit Amid Mixed Economic Signals and Rising Energy Costs

8 de ago. de 2026, 20:31 UTC

China's Q2 2026 Current Account Data Release Expected to Show Continued Surplus Growth Amidst Global Economic Pressures

8 de ago. de 2026, 20:11 UTC

Eurozone Industrial Production MoM data for June 2026 expected to show flat growth amid concerns over declining output and geopolitical tensions.

8 de ago. de 2026, 20:01 UTC

South Africa's Q2 Unemployment Rate Set for Release Amidst Rising Global Job Concerns, Following Alarming 32.7% in Q1

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

26.8% parte superior

Previsão para 12 meses

Média 53.75 USD 26.8%

Máximo 60 USD

Mínimo 45 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.